Next Article in Journal / Special Issue
Blend Hydrogel Microspheres of Carboxymethyl Chitosan and Gelatin for the Controlled Release of 5-Fluorouracil
Previous Article in Journal
A Robust Liquid Chromatographic Method for Confirmation of Drug Stability of Azithromycin in Bulk Samples, Tablets and Suspensions
Previous Article in Special Issue
Doxorubicin Delivery Using pH and Redox Dual-Responsive Hollow Nanocapsules with a Cationic Electrostatic Barrier
Open AccessReview

Liposomal Formulations in Clinical Use: An Updated Review

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad 500037, India
*
Author to whom correspondence should be addressed.
Pharmaceutics 2017, 9(2), 12; https://doi.org/10.3390/pharmaceutics9020012
Received: 16 January 2017 / Revised: 20 March 2017 / Accepted: 23 March 2017 / Published: 27 March 2017
(This article belongs to the Special Issue Nanotechnology in Medical Therapeutic Formulations)
Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications. These closed bilayer phospholipid vesicles have witnessed many technical advances in recent years since their first development in 1965. Delivery of therapeutics by liposomes alters their biodistribution profile, which further enhances the therapeutic index of various drugs. Extensive research is being carried out using these nano drug delivery systems in diverse areas including the delivery of anti-cancer, anti-fungal, anti-inflammatory drugs and therapeutic genes. The significant contribution of liposomes as drug delivery systems in the healthcare sector is known by many clinical products, e.g., Doxil®, Ambisome®, DepoDur™, etc. This review provides a detailed update on liposomal technologies e.g., DepoFoam™ Technology, Stealth technology, etc., the formulation aspects of clinically used products and ongoing clinical trials on liposomes. View Full-Text
Keywords: liposomes; therapeutics; drug delivery; liposome technology; nanotechnology; clinical trials; marketed products liposomes; therapeutics; drug delivery; liposome technology; nanotechnology; clinical trials; marketed products
Show Figures

Figure 1

MDPI and ACS Style

Bulbake, U.; Doppalapudi, S.; Kommineni, N.; Khan, W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 2017, 9, 12. https://doi.org/10.3390/pharmaceutics9020012

AMA Style

Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics. 2017; 9(2):12. https://doi.org/10.3390/pharmaceutics9020012

Chicago/Turabian Style

Bulbake, Upendra; Doppalapudi, Sindhu; Kommineni, Nagavendra; Khan, Wahid. 2017. "Liposomal Formulations in Clinical Use: An Updated Review" Pharmaceutics 9, no. 2: 12. https://doi.org/10.3390/pharmaceutics9020012

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop